Malignant Melanoma Archive - Seite 12 von 19 - IOZK

Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination

2008-09-19/in International Publications, Malignant Melanoma /von 2008-09-19 / J. Dermatol. Sci. 2009 Jan;53(1):40-7

Melanoma vaccines

2008-09-01/in International Publications, Malignant Melanoma /von 2008-09-01 / Expert Rev Vaccines 2008 Sep;7(7):937-49

Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

2008-08-22/in International Publications, Malignant Melanoma /von 2008-08-22 / Cancer Immunol. Immunother. 2009 Jan;58(1):1-14

Dendritic cell vaccines in metastasized malignant melanoma

2008-08-01/in Dendritic Cells, International Publications, Malignant Melanoma /von 2008-08-01 / G Ital Dermatol Venereol 2008 Aug;143(4):235-50

TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis

2008-07-11/in Hyperthermia, International Publications, Malignant Melanoma /von 2008-07-11 / Cancer Immunol. Immunother. 2009 Mar;58(3):361-71

Strategies to overcome obstacles to successful immunotherapy of melanoma

2008-07-01/in International Publications, Malignant Melanoma /von 2008-07-01 / Int J Immunopathol Pharmacol 2008 Jul-Sep;21(3):493-500

Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma

2008-07-01/in International Publications, Malignant Melanoma /von 2008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-51

Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor

2008-07-01/in International Publications, Malignant Melanoma /von 2008-07-01 / J. Clin. Oncol. 2008 Jul;26(19):3235-41

IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma

2008-07-01/in International Publications, Malignant Melanoma /von 2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):555-62

Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma

2008-07-01/in International Publications, Malignant Melanoma /von 2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):591-8